Clarification of weight-based heparin protocol

Clarification of once-daily low-molecular-weight heparin dosing in pulmonary embolism.

We appreciate the interest demonstrated by Dr Girard and his colleagues in our work. 1 We agree that we cannot completely rule out a selection bias as a mechanism of our fi ndings and have acknowledged this in the “Limitations” section of our article. Despite robustly adjusting for severity of illness in our multivariable regression model, we cannot exclude residual confounding. The “Monday Eff...

Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight.

STUDY OBJECTIVES To develop and validate an improved unfractionated heparin (UFH) dosage protocol, using antifactor Xa levels as the outcome variable. DESIGN Prospective case series. SETTING A 625-bed, adults-only private, tertiary care teaching hospital. PATIENTS Three hundred seventy-two patients receiving UFH for eight different indications were in the protocol derivation group. One hu...

Heparin and low-molecular-weight heparin.

Heparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have repl...

Evaluation of 2 weight-based protocols for administration of heparin.

BACKGROUND In 1996, a weight-based protocol for administration of heparin was implemented and assessed at the authors' institution. Since then, several modifications have been made, including introduction of a lower-target protocol. These changes warranted re-evaluation of the standard and lower-target protocols. OBJECTIVE To determine and compare the efficacy and safety of the standard and l...

Low molecular weight heparin.